2. Academic Validation
  3. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

  • Oncoimmunology. 2013 Dec 1;2(12):e26852. doi: 10.4161/onci.26852.
Vidyalakshmi Chandramohan 1,  Darell D Bigner 1
Affiliations

Affiliation

  • 1 Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center; Durham, NC USA ; Department of Pathology; Duke University Medical Center; Durham, NC USA.
PMID: 24498557 DOI: 10.4161/onci.26852
Abstract

Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas.

Keywords

Pseudomonasexotoxin; bispecific antibody; brain tumors; convection-enhanced delivery; glioma-associated antigens.

Figures
Products